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Abstract 
The high prevalence of end-stage renal disease emphasizes the failure to provide 
therapies to effectively prevent and/or reverse renal fibrosis. Therefore, the aim of this 
study was to evaluate the effect of long-term treatment with chaethomellic acid A 
(CAA), which selectively blocks Ha-Ras farnesylation, on renal mass reduction-induced 
renal fibrosis. Male Wistar rats were sham-operated (SO) or subjected to 5/6 renal mass 
reduction (RMR). One week after surgery, rats were placed in four experimental groups: 
SO: SO rats without treatment (n=13); SO+CAA: SO rats treated with CAA (n=13); 
RMR: RMR rats without treatment (n=14); and RMR+CAA: RMR rats treated with 
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CAA (n=13). CAA was intraperitoneally administered in a dose of 0.23 µg/Kg three 
times a week for six months. Renal fibrosis was evaluated by two-dimensional 
ultrasonography and histopathological analysis. The kidneys of the RMR animals 
treated with CAA showed a significantly decrease in the medullary echogenicity 
(p<0.05) compared with the RMR rats that received no treatment. Glomerulosclerosis 
and arteriolosclerosis scores were significantly lower (p<0.001) in the RMR+CAA 
group when compared with the RMR group. There were no significant differences in 
interstitial fibrosis, interstitial inflammation and tubular dilatation scores between the 
RMR+CAA and RMR groups. These data suggest that CAA can be a potential future 
drug to attenuate the progression of chronic kidney disease. 
Keywords: Wistar rats, 5/6 renal mass reduction model, chaetomellic acid A, Ha-Ras 
protein, renal fibrosis 
Abbreviations: CAA, chaethomellic acid A; CKD, chronic kidney disease; ECM, 
extracellular matrix proteins; EMT, epithelial-to-mesenchymal transition; ESRD, end-
stage renal disease; IRI, renal ischemia-reperfusion injury; KO, knock-out; RMR, 5/6 
renal mass reduction; SBP, systolic blood pressure; SO, sham-operated; TGF-β1, 
transforming growth factor-β1; UUO, unilateral ureteral obstruction; 𝛼-SMA, alpha-
smooth muscle actin. 
 
 
1. Introduction 
Chronic kidney disease (CKD) is an important challenge for health-care systems 
worldwide [1]. The natural course of the CKD is to progress towards end-stage renal 
disease (ESRD) and death, unless dialysis or transplant is implemented [2]. Regardless 
of the initial cause, development of renal fibrosis is the hallmark of most progressive 
CKD [3]. Therefore, targeting the components of the fibrogenic pathways can be a 
therapeutic approach to inhibit or slow the progression of CKD to ESRD. 
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The Ras proteins – small monomeric GTPase of 21 kDa – are important 
mediators in the development of renal fibrosis [4-8] and thereby could be a potential 
therapeutic target against fibrotic nephropathies. These proteins are located in different 
plasma-membrane microdomains and subcellular compartments where activate several 
signalling pathways. The best characterized signalling pathways are: the Ras/Raf/MEK-
ERK1/2, which is responsible for the induction of several cellular responses such as cell 
growth, differentiation and apoptosis; and the Ras/PI3K/Akt, which is implicated in 
regulation of cell metabolism, cell motility and promotion of cell survival protecting 
cells from apoptosis [9-11]. Activation of these signalling pathways has been reported 
as mediators in renal fibrosis [4,7,8].  
There are three closely related major isoforms of Ras proteins: Harvey (Ha)-, 
Kirsten (Ki)-, and neural (N)-Ras, which are expressed in mammalian cells and have 
different biological effects [9,12-14], namely in fibroblasts biology and fibrotic 
processes [6,15-17]. It has been reported that depletion of Ha-Ras isoform in cultured 
fibroblasts obtained from Ha-Ras knock-out (KO) mice up-regulates extracellular 
matrix proteins (ECM) synthesis and mediates proliferation and migration by 
modulating PI3K/Akt and MEK/ERK activation [16,17]. In an in vivo study, fibrosis 
was lower in H-Ras KO than in wild type mice after unilateral ureteral obstruction 
(UUO) [4]. Therefore, inhibition of Ha-Ras isoform could be used as a potential 
therapeutic strategy to reduce fibrosis development. 
Chaetomellic acid A (CAA) has been identified as a highly specific inhibitor of 
farnesyl transferase [18], which selectively blocks Ha-Ras farnesylation [19]. Sabbatini 
et al. [20] have demonstrated that pre-treatment with CAA of human renal proximal 
tubular cells or human umbilical vein endothelial cells significantly reduced apoptosis. 
The same researchers have also observed that in acute renal ischemia-reperfusion injury 
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(IRI) model in rats, CAA administration preserves both renal function and histological 
damage [20,21]. Furthermore, in a rat model of excitotoxic lesion, CAA treatment 
increased the intracellular concentration of inactive Ha-Ras, leading to a marked 
decrease of superoxide anion production [19]. In another in vivo study, CAA 
administration reduced renal damage after UUO in mice [7]. However, up to now, all 
the studies performed on the effect of CAA in renal fibrosis have been performed in 
vitro or in rapid models of renal fibrosis such as UUO. 
Thus, in this study we aimed to evaluate the effect of long-term treatment with 
CAA on renal fibrosis in rats with 5/6 renal mass reduction (RMR), a model similar to 
renal fibrosis observed in CKD [22]. 
 
2. Materials and Methods 
2.1. Animals and experimental conditions 
Sixty male Wistar rats (weighing approximately 135 g) were acquired from 
Harlan-Interfauna (Barcelona, Spain). Rats were housed in standard cages (Tecniplast, 
Buguggiate, Italy) with corncob for bedding (Mucedola, Milan, Italy) in a controlled 
room: 12/12 hours’ light-dark cycle, temperature (23±2ºC) and humidity (50±10%); 
animals were fed with a standard rat chow (Mucedola
®
, Milan, Italy) and water ad 
libitum. All experimental procedures followed the European (European Directive 
2010/63/EU) and National (Decree-Law 113/2013) legislation on the protection of the 
animals used for scientific purposes. 
2.2. Experimental design 
After seven weeks of acclimatization, rats (weighing 359 to 402 g) were sham-
operated (SO) or submitted to RMR. All surgical procedures were carried out under 
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general anaesthesia (ketamine/xylazine, 70/10 mg/kg; intraperitoneally) and aseptic 
conditions. The animals assigned to the RMR groups (n=34) were subjected to 5/6 
RMR by surgical resection through a midline laparotomy, as described previously [23]. 
The right kidney was exposed, decapsulated and removed. Then, the left kidney was 
exposed, decapsulated and both the upper and lower poles (two thirds of the left kidney) 
were resected. Excised kidney and poles were weighed immediately after removal. The 
sham-operated group rats (n=26) underwent the same abdominal incision and 
manipulation of the right and the left kidneys without removal of renal mass. Special 
care was taken to prevent damage to the adrenal glands during the surgeries. The 
percentage of renal tissue removed was calculated based on the removed tissue, 
assuming that the right and left kidneys had equal weights. Two days after renal mass 
reduction, serum creatinine was measured (Daytona® Rx, Randox). Rats weights were 
recorded weekly. Animals were daily observed to assess their general health and 
mortality. 
One week after surgery surviving animals (n=53) were distributed into four 
groups: SO: SO rats receiving no treatment (n=13); SO+CAA: SO rats receiving CAA 
treatment (n=13); RMR: RMR rats receiving no treatment (n=14); RMR+CAA: RMR 
rats receiving CAA treatment (n=13). Rats from SO groups were distributed randomly 
and the animals from RMR groups were distributed according to the serum creatinine 
concentrations and the percentage of the removed renal tissue to ensure equal reduction 
in renal mass. CAA was intraperitoneally administered (0.23 µg/Kg; Santa Cruz 
Biotechnology, California, USA) [21] three times a week for six months.  
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2.3. Ultrasonographic evaluation 
Six months after the surgical procedure, in the left kidney of each animal was 
evaluated the mean cortical and medullary echogenicity by ultrasonography using two-
dimensional ultrasonography (B mode) as reported previously by Nogueira et al. [24] 
(Figure 1). 
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Figure 1. Measurement of mean pixels (echogenicity) in the renal cortex (A and C) and renal 
medulla (B and D) of the sham-operated rats (SO) (A and B) and rats with 5/6 renal mass 
reduction (RMR) (C and D). 
 
 
 
2.4. Renal function assessment 
Blood and urine samples were collected at the sixth month as we have 
previously described [25]. Plaα creatinine, urinary creatinine and proteinuria were 
measured using a chemistry analyser (Daytona® Rx, Randox) as per manufacturers' 
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instructions. Creatinine clearance was calculated according to standard formula [Uc x 
V/Pc, where Uc= urine creatinine (mg/dl), V= urine volume (ml/min/100 g body 
weight) and Pc= plasma creatinine (mg/dl)]. 
 
2.5. Animals’ sacrifice 
 Six months after the surgery, surviving animals were anesthetized with 
isoflurane. Systolic blood pressure (SBP) was measured through femoral artery 
catheterization as we have previously described [25]. After that, the rats were sacrificed 
using an overdose of anesthesia followed by exsanguination by cardiac puncture as 
indicated by the Federation of European Laboratory Animal Science Associations [26]. 
A complete necropsy was performed, either the remnant kidney from RMR rats or both 
kidneys from SO rats were removed, weighed and examined macroscopically.  Relative 
left kidney weights were calculated as the ratio of the left kidney weight to the rats’ total 
body weight [27]. 
 
2.6. Renal fibrosis evaluation 
 Samples were fixed in neutral buffered formalin 10%, embedded in paraffin 
wax, by routine methods, and 2 μm thick sections, including renal cortex and medulla, 
were stained for routine histopathological diagnosis with Haematoxylin and Eosin (HE), 
Masson’s trichrome and Reticulin special stains. Renal fibrosis was evaluate under light 
microscopy by two different researchers blindly and scored as previously reported by 
Asaba et al. [28]: glomerulosclerosis (0: normal; 1: matrix expansion or sclerosis less 
than 25%; 2: 26-50%; 3: 51-75%; and 4: more than 75%); interstitial fibrosis (0: 
normal; 1: mild fibrosis around vasculature; 2: mild fibrosis around tubules; 3: moderate 
fibrosis with tubular casts or tubular damage; and 4: severe fibrosis with cell 
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infiltration) and arteriolosclerosis (0: normal; 1: medial thickening; 2: segmental 
hyalinosis; 3: global hyalinosis; and 4: luminal occlusion with thrombus or infiltrating 
cells). The interstitial inflammation (presence of aggregates of lymphocytes and 
neutrophils in the interstitium) and the tubular dilatation (significant increase in luminal 
diameter, more than two folds, associated with flattening of the epithelial lining) were 
assessed according to Moubarak et al. [29] (0: not present; 1: minimal damage with rare 
and small foci; 2: mild damage with few and small foci; and 3: moderate damage with 
frequent and moderately sized foci). The average of each score was calculated for each 
rat. 
2.7. Statistical analysis 
Data were analysed with SPSS
® 
(version 23 for Windows; IBM Corp., Armonk, 
NY, USA). Results are presented as mean ± standard error (SE). The normality of the 
data was checked with the Shapiro-Wilk test. Statistical differences between groups 
were assessed by one-way analysis of variance (ANOVA) for independent samples, 
followed by Tukey HSD post hoc tests, when the data was normally distributed. In the 
other cases, the Kruskal-Wallis test was used, followed by multiple comparisons by 
Dunn’s procedure. Differences between groups were considered statistically significant 
if p<0.05. 
3. Results 
3.1. General data and renal function 
 Two animals from RMR group and five animals from RMR+CAA group died 
during the experimental protocol. The data from these animals were not included in the 
study and the size of the groups was reduced to 12 animals in RMR group and 8 animals 
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in RMR+CAA group. Statistically significant differences concerning body weight, left 
kidney weight and left kidney weight/ body weight ratio were found between SO and 
RMR groups (p<0.05). As expect, at end of experimental protocol (6 months), in RMR 
groups the values of SBP was significantly higher compared with SO groups; and rats 
from RMR groups showed clinical signs of CKD characterized by significant reduction 
in creatinine clearance and significant increase in urinary protein loss in comparison to 
sham-operated controls rats (p<0.05) (Table 1). 
 
Table 1. Body weight, left kidney weight, left kidney weight/body weight ratio, systolic blood 
pressure, creatinine clearance and proteinuria and at the end of the experimental protocol (6 months) 
(mean ± standard error). 
 
SO 
(n = 13) 
SO+CAA 
(n = 13) 
RMR 
(n = 12) 
RMR+CAA 
(n = 8) 
p
(1)
 
Body weight (g) 560±16
a
 550±10
ab
 516±13
ab
 503±12
b
 0.015 
Left Kidney weight (g) 1.35±0.03
a
 1.29±0.03
a
 2.32±0.14
b
 1.97±0.12
b
 < 0.001 
Left Kidney weight/Body weight 
ratio (%) 
0.24±0.01
a
 0.24±0.01
a
 0.45±0.03
b
 0.39±0.03
b
 < 0.001 
Systolic blood pressure (mmHg) 148.22 ±6.36
a
 146.00± 5.32
a
 202.22±9.61
b
 184.29± 9.79
b
 < 0.001 
Creatinine clearance (ml/min) 1.56±0.04
a
 1.45±0.09
a
 0.73±0.10
b
 0.92±0.11
b
 < 0.001 
Proteinuria (g/day) 0.105±0.006
a
 0.117±0.09
a
 3.167±0.410
b
 2.467±0.758
b
 < 0.001 
(1)
 Significance value of the ANOVA. Groups with different letters were considered statistically different 
(p<0.05 in the Tukey HSD post hoc tests). SO: sham-operated rats; SO + CAA: sham-operated rats 
treated with chaetomellic acid A; RMR: rats with 5/6 renal mass reduction; RMR + CAA: rats with 5/6 
renal mass reduction treated with chaetomellic acid A. 
 
 
3.2. Kidney echogenicity 
Renal echogenicity was evaluated in cortex and medulla in all experimental 
groups at the end of the study. The echogenicity of cortex and medulla was higher in 
both RMR groups when compared with SO groups (p<0.05). The CAA administration 
decreased the cortical and medullary echogenicity in RMR rats, however only with 
statistically significance for medullary echogenicity (p<0.05) (Figure 2). 
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Figure 2. Echogenicity of renal cortex and medulla in all experimental groups at the end of the 
experimental protocol (6 months). SO: sham-operated rats; SO + CAA: sham-operated rats 
treated with chaetomellic acid A; RMR: rats with 5/6 renal mass reduction; RMR + CAA: rats 
with 5/6 renal mass reduction treated with chaetomellic acid A (Kruskal-Wallis Test. Groups 
with different letters were considered statistically different - p<0.05 in the multiple comparisons 
by Dunn’s procedure). 
 
3.3. Histopathological studies 
The results of the evaluation of glomerulosclerosis, interstitial fibrosis, 
arteriolosclerosis, interstitial inflammation and tubular dilatation are given in Table 2; 
and the distribution by different grades of severity in these histological lesions for all 
experimental groups can be seen in the Table 3. Rats from SO groups presented no 
kidney histological changes: kidney tissue displayed a normal morphology with intact 
glomeruli and tubules (Figure 3a, 3b, 3c, 3d, 3e and 3f), although some animals showed 
minimal to mild interstitial inflammation (Table 3). The RMR rats that received no 
treatment showed severe glomerulosclerosis, interstitial fibrosis, interstitial 
inflammation, arteriolosclerosis and tubular dilatation (Table 2 and 3; Figure 3g, 3h and 
3i). In the RMR rats that received CAA, the severity of glomerulosclerosis and 
arteriolosclerosis was significantly reduced compared with RMR rats that received no 
treatment. The degree of interstitial fibrosis, interstitial inflammation and tubular 
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dilatation was also reduced in the RMR rats that received CAA compared with the 
RMR rats that received no treatment; however, these differences were not statistically 
significant (Table 2 and 3; Figure 3j, 3k and 3l). 
Table 2. Scores of renal fibrosis, inflammation and tubular dilatation at the end of the experimental protocol (6 
months) (mean ± standard error). 
  Scores 
SO  
(n = 13) 
SO+CAA  
(n = 13) 
RMR  
(n = 12) 
RMR+CAA  
(n = 8) 
p
(1)
 
Glomerulosclerosis score 0.00±0.00
a
 0.00±0.00
a
 3.42±0.19
b 
1.88±0.35
c 
< 0.001 
Interstitial fibrosis score 0.00±0.00
a
 0.00±0.00
a
 3.25±0.14
b
 2.17±0.35
b
 < 0.001 
Arteriolosclerosis score 0.00±0.00
a
 0.00±0.00
a
 1.83±0.37
b 
0.50±0.38
a
 < 0.001 
Interstitial inflammation score 0.31±0.13
a
 0.15±0.15
a
 3.00±0.00
b
 2.50±0.27
b
 < 0.001 
Tubular dilatation score 0.00±0.00
a
 0.00±0.00
a
 3.00±0.00
b
 1.88±0.35
b
 < 0.001 
(1)
 Significance value of the Kruskal-Wallis Test. Groups with different letters were considered statistically different SO: 
sham-operated rats; SO + CAA: sham-operated rats treated with chaetomellic acid A; RMR: rats with 5/6 renal mass 
reduction; RMR + CAA: rats with 5/6 renal mass reduction treated with chaetomellic acid A (p<0.05 in the multiple 
comparisons by Dunn’s procedure). 
 
Table 3. Distribution by different grades of severity in the different histological lesions. 
Histological lesion SO  
(n = 13) 
SO+CAA 
 (n = 13) 
RMR  
(n = 12) 
RMR+CAA 
(n = 8) 
Glomerulosclerosis     
0. Normal 13 (100.0%) 13 (100.0%) 0 (0.0%) 0 (0.0%) 
1. ≤ 25% 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (37.5%) 
2. 26 – 50% 0 (0.0%) 0 (0.0%) 1 (8.3%) 4 (50.0%) 
3. 51 – 75% 0 (0.0%) 0 (0.0%) 5 (41.7%) 0 (0.0%) 
4. > 75% 0 (0.0%) 0 (0.0%) 6 (50.0%) 1 (12.5%) 
Interstitial fibrosis     
0. Normal 13 (100.0%) 13 (100.0%) 0 (0.0%) 0 (0.0%) 
1. Mild fibrosis around vasculature 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (25.0%) 
2. Mild fibrosis around tubules 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (50.0%) 
3. Moderate fibrosis with tubular casts or tubular 
damage 
0 (0.0%) 0 (0.0%) 9 (75.0%) 1 (12.5%) 
4. Severe fibrosis with cell infiltration  0 (0.0%) 0 (0.0%) 3 (25.0%) 1 (12.5%) 
Arteriolosclerosis     
0. Normal 13 (100.0%) 13 (100.0%) 1 (8.3%) 6 (75.0%) 
1. Medial thickening 0 (0.0%) 0 (0.0%) 6 (50.0%) 1 (12.5%) 
2. Segmental hyalinosis 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
3. Global hyalinosis 0 (0.0%) 0 (0.0%) 4 (33.3%) 1 (12.5%) 
4. Luminal occlusion with thrombus or 
infiltrating cells 
0 (0.0%) 0 (0.0%) 1 (8.3%) 0 (0.0%) 
Interstitial inflammation     
0. Not present 9 (69.2%) 12 (92.3%) 0 (0.0%) 0 (0.0%) 
1. Minimal with rare and small foci 4 (30.8%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 
2. Mild damage with few and small foci 0 (0.0%) 1 (7.7%) 0 (0.0%) 2 (25.0%) 
3. Moderate damage with frequent and 
moderately sized foci 
0 (0.0%) 0 (0.0%) 12 (100.0%) 5 (62.5%) 
Tubular dilatation     
0 Not present 13 (100.0%) 13 (100.0%) 0 (0.0%) 1 (12.5%) 
1 Minimal 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 
2 Mild 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (50.0%) 
3 Moderate 0 (0.0%) 0 (0.0%) 12 (100.0%) 2 (25.0%) 
SO: sham-operated rats; SO + CAA: sham-operated rats treated with chaetomellic acid A; RMR: rats with 
5/6 renal mass reduction; RMR + CAA: rats with 5/6 renal mass reduction treated with chaetomellic acid 
A. 
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Figure 3. Representative kidney sections from sham-operated rats (SO), sham-operated rats treated with 
chaetomellic acid A (SO+CAA), rats with 5/6 renal mass reduction (RMR) and rats with 5/6 renal mass reduction 
treated with chaetomellic acid A (RMR+CAA) stained with Haematoxylin and Eosin (HE), Masson’s trichrome 
and reticulin stain. SO group: a, b and c – normal kidney morphology (x200); SO+CAA: d, e and f– normal kidney 
morphology (x200); RMR: g – arteriolosclerosis (grade 4); not also the interstitial inflammation (x400); h – 
glomerulosclerosis (grade 4) (x400); i – interstitial fibrosis (grade 3) (x200); and RMR+CAA: j – arteriolosclerosis 
(grade 0) (x400); k – glomerulosclerosis (grade 2) (x400); l– interstitial fibrosis (grade 2) (x200).  
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4. Discussion 
 
 
Development of renal fibrosis is the hallmark of most progressive CKD, 
regardless of its primary aetiology [3]. Therefore, treatment strategies aimed at 
preventing or slowing its devastating sequelae and progression to ESRD are of greatest 
importance. 
Some studies highlight the importance of Ha-Ras isoform in the development of 
fibrosis [4,16,17]. Therefore, we have evaluated the effect of CAA, which selectively 
blocks Ha-Ras farnesylation [19], on renal fibrosis. To date, relatively few studies have 
assessed the effects of the CAA in experimental models of kidney diseases [7,20,21,25]. 
To our knowledge this is the first study that evaluated the effect of long-term CAA 
treatment on renal fibrosis in rats with progressive renal disease. In the present study, 
we have demonstrated that CAA (23 µg/Kg, three times a week, for six months) 
attenuate renal fibrosis, particularly glomerulosclerosis. Our results confirm the 
capability of CAA to reduce renal fibrosis observed in the IRI and UUO rodent models 
by Sabbatini et al. [20,21] and Rodriguez-Peña et al. [7], respectively. 
In most patients, CKD progresses to an end point with common histological 
features characterized by accumulation of ECM in glomeruli and interstitium, which 
leads to generalized fibrosis and tubular atrophy [30]. Therefore, the acceptable animal 
model for the study of renal fibrosis should provide the development of 
glomerulosclerosis and interstitial fibrosis to a comparable extent to what is observed in 
human medicine.  One of the most commonly animal models used to study renal disease 
progression is the 5/6 RMR in rats, which we used to evaluate the effect of CAA on 
renal fibrosis. 
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In this animal model, the increase in the glomerular filtration rate and blood flow 
associated with glomerular hypertension is followed by progressive deterioration of 
renal function accompanied by severe proteinuria and by structural renal changes such 
as glomerulosclerosis, tubulointerstitial fibrosis and vascular sclerosis [31,32]. In this 
study, after six months of RMR rats showed typical features of CKD: systemic 
hypertension, renal failure, proteinuria and renal fibrosis, which proved that RMR had 
been successfully performed. 
In the present study, no deaths were observed in SO groups. However, among 
the RMR groups, the mortality was higher in the rats treated with CAA, despite the 
deaths had occurred only after the fifth month after RMR. According to Qian et al. [33], 
CAA has a reduced off-target toxicity relative to others farnesyltransferase inhibitors. In 
fact, as we have previously discussed [25], we did not observe adverse effects after the 
administration of CAA to rats. However, possibly chronic administration of CAA (0.23 
µg/Kg three times a week) may have some toxicity in rats with CKD, while in healthy 
animals, administration of CAA is innocuous. 
 Renal fibrosis was evaluated by ultrasonography and histopathological analysis. 
Ultrasonography is a real-time imaging technique, noninvasive and non-nephrotoxic 
[34].  An increase of renal echogenicity is considered an indicator of renal fibrosis [35]. 
In fact, we have previous observed that the cortical and medullary echogenicity is a 
good marker of fibrosis in the 5/6 RMR model [24]. In this study, the kidneys of RMR 
animals treated with CAA showed a decrease in the cortical and medullary echogenicity 
compared with RMR rats that received no treatment; however, the difference was only 
statistically significant for medullary echogenicity. So, the results obtained by 
ultrasonography suggest that CAA has a beneficial effect on renal fibrosis. These results 
are in agreement with those obtained in histopathological studies, in which we observed 
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that in comparison with RMR group, the kidneys from RMR+CAA group showed 
significantly reduced glomerulosclerosis and arteriolosclerosis. Kidneys from 
RMR+CAA group also exhibited less interstitial fibrosis, interstitial inflammation and 
tubular dilatation.  
Histopathological studies of renal tissue after RMR reveal the presence of three 
phases: rapid hypertrophic phase (2 to 4 weeks after RMR); phase with minimal 
histological changes (4 to 10 weeks); and the development of segmental glomerular 
sclerosis and tubulointerstitial fibrosis (after 10 weeks) [36]. Several authors have 
observed that during the different phases numerous molecules such as cytokines and 
growth factors [37,38,39], growth factor receptors [38], and extracellular matrix 
glycoproteins [40] are overexpressed in renal tissue. In this model, was also observed 
the activation of the Raf/ MAPKs-ERK [41] and PI3K/Akt [42] pathways – the mainly 
Ras signaling pathways. Activation of Ras and its signaling pathways Raf/ MEK-
ERK1/2 and PI3K/Akt has been described as mediators in progressive renal damage 
[43,44]. In a model of renal fibrosis induced by UUO, renal fibrosis was associated to 
Ras, ERK, and Akt activations, with main involvement of ERK1/2 in apoptotic events 
and Akt in proliferative and fibrotic response [45].  Many growth factors are known to 
activate intracellular signaling pathways that converge on Ras activation, including 
transforming growth factor-β1 (TGF-β1) [9,10]. The production of TGF-β1, both by 
intrinsic renal cells and infiltrated inflammatory cells, plays a key role in the 
pathological deposition of extracellular matrix after damage to renal tissue [46]. There 
is a close relationship between TGF-β1, Ras signaling pathways and epithelial-to-
mesenchymal transition (EMT). EMT plays an important role in the renal fibrosis 
[47,48]. Grande et al. [4] demonstrated in the UUO model performed in mice the 
relationship between H-Ras and EMT in the kidney and its contribution to the 
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development of renal fibrosis. These authors observed that Ha-Ras deficiency reduces 
fibrogenesis, activation of Akt, the amount of activated myofibroblasts, and EMT 
inducers. It also impairs interstitial fibroblast proliferation and decreases TGF-β1-
induced proliferation and motility in fibroblasts. CAA administration decreased Ras 
downstream signalling pathways, MAPK-ERK1/2 and PI3K/Akt, as well as alpha-
smooth muscle actin (𝛼-SMA) accumulation (a marker for myofibroblasts) in UUO 
kidneys [7[. In addition, it has been reported that the inhibition of farnesylation by CAA 
inhibits Ras/ERK1/2 pathway and significantly reduces acute postischemic renal injury 
in rats [20].  Thus, through the modulation of Raf/MEK/ERK and PI3K-Akt pathways, 
CAA may have attenuate RMR-induced renal fibrosis.  
 
In 5/6 RMR, the presence of infiltrated cells plays an essential role in the 
progression of renal parenchymal lesion [49,50]. An abnormal, persistent inflammatory 
response may lead to increased synthesis and deposition of ECM with subsequent 
fibrosis [51]. It was also observed that inflammation can induce EMT [52]. In this 
study, the interstitial inflammation score was higher in RMR group compared with 
RMR+CAA group, although this difference was not statistically significant. Therefore, 
this higher infiltration of inflammatory cells present in the kidney samples of animals 
belonging to the RMR group may have contributed to a much more pronounced 
development of renal fibrosis in this group. 
Another potential mechanism responsible for the beneficial effects of CAA on 
renal fibrosis could involve the reduction of oxidative stress. Oxidative stress resulting 
in generation of reactive oxygen species (ROS), mainly in the form of superoxide and 
hydrogen peroxide, plays a significant role in the initiation and progression of renal 
disease [53,54]. NADPH oxidase has been identified as the enzyme system most 
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responsible for superoxide generation by adventitial fibroblasts [55,56] and it is 
recognized as a key mediator of cell proliferation, matrix accumulation [57,58], and 
EMT [52] in renal disease. Activated Ha-Ras isoform increase intracellular levels of 
ROS via up-regulation of the plasma membrane NADPH oxidase [59-61]. CAA inhibits 
Ras/ERK1/2 pathway and protects human renal proximal tubular cells from oxidative 
stress-induced cell death [20]. Furthermore, CAA administration in rats, after brain 
damage induced by an excitotoxic stimulus, significantly reduced superoxide 
production [19]. Also, an in our previous study [25], we have observed that CAA 
attenuate 5/6 RMR-induced oxidative stress in rats. Oxidative stress plays an important 
role in renal injury induced by 5/6 RMR [62,63]. Thus, the reduction of oxidative stress 
by CAA may also have contributed to the decrease of renal fibrosis seen in the rats 
treated with CAA. 
 
5. Conclusion 
 
Under our experimental conditions, CAA (23 µg/Kg, three times a week, for six 
months) reduced renal fibrosis, mainly glomerulosclerosis and arteriolosclerosis, in a rat 
model of CKD. Although further studies are necessary, the data of this study suggests 
that the inhibition of farnesylation of Ha-Ras protein by CAA can be a possible new 
therapeutic target to attenuate the progression of CKD. The precise mechanisms by 
which CAA prevents the progression of renal fibrosis cannot be elucidated by this 
study. However, on the basis of previous studies we can suggest that its protective 
effects on renal fibrosis observed in this study may be based mainly on its ability to 
modulate Raf/MEK/ERK and PI3K-Akt pathways and consequently cell proliferation 
and EMT. In this study, the mortality was higher in the rats with CKD treated with 
18 
 
CAA, although no adverse effects were observed in sham-operated treated rats. These 
data highlight the need for more studies on the CAA clinical toxicity and safety. 
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